- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00125125
Fluvastatin in Adults With Dislipidemia With History of Muscle Problems
May 15, 2017 updated by: Novartis
Efficacy and Tolerability of Fluvastatin in Adults With Dislipidemia With History of Muscle Problems Due to Other Previous Statin Intake
The purpose of the study is to find a good therapy for patients who need to be treated for high cholesterol and who have difficulty tolerating other statins (such as pravastatin, simvastatin, lovastatin, atorvastatin, rosuvastatin) due to muscle pain.
Study Overview
Study Type
Interventional
Enrollment (Actual)
218
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Investigative Centers, Germany
-
-
-
-
New Jersey
-
East Hanover, New Jersey, United States, 07936
- Novartis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Dyslipidemia
- History of Myalgia
Exclusion Criteria:
- Previous treatment with fluvastatin
- Age < 18 years
Other protocol-defined inclusion and exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Change from baseline in low density lipoprotein cholesterol after 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
---|
Tolerability as assessed by muscle-related adverse events, and muscle-related adverse events leading to discontinuation
|
Change from baseline in total cholesterol, triglycerides, high density lipoprotein cholesterol, and lipoprotein subtypes after 12 weeks
|
Number of patients who reach target LDL after 12 weeks
|
Change from baseline in marker of inflammation after 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2005
Primary Completion (Actual)
December 1, 2005
Study Completion (Actual)
December 1, 2005
Study Registration Dates
First Submitted
July 28, 2005
First Submitted That Met QC Criteria
July 28, 2005
First Posted (Estimate)
July 29, 2005
Study Record Updates
Last Update Posted (Actual)
May 17, 2017
Last Update Submitted That Met QC Criteria
May 15, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CXUO320B2406
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyslipidemia
-
Kowa Research Institute, Inc.CompletedMixed Dyslipidemia | Primary DyslipidemiaUnited States
-
Chong Kun Dang PharmaceuticalCompletedDyslipidemia (Fredrickson Type Ⅱa) | Dyslipidemia (Fredrickson Type Ⅱb)Korea, Republic of
-
Hanlim Pharm. Co., Ltd.RecruitingMixed DyslipidemiaKorea, Republic of
-
IlDong Pharmaceutical Co LtdNot yet recruiting
-
Arrowhead PharmaceuticalsCompletedMixed DyslipidemiaUnited States, Australia, Poland, New Zealand, Canada, Hungary
-
Provident Clinical ResearchReliant PharmaceuticalsCompleted
-
Arrowhead PharmaceuticalsActive, not recruitingMixed DyslipidemiaUnited States, Australia, Canada, New Zealand
-
Yooyoung Pharmaceutical Co., Ltd.CompletedCombined DyslipidemiaKorea, Republic of
-
Société des Produits Nestlé (SPN)CompletedPrimary DyslipidemiaChina
-
Provident Clinical ResearchReliant PharmaceuticalsUnknown
Clinical Trials on Fluvastatin
-
Novartis PharmaceuticalsCompleted
-
Bader, Ted, M.D.US Department of Veterans AffairsCompleted
-
NovartisCompleted
-
AORTICA GroupTerminated
-
NovartisCompletedHypercholesterolemia | Mixed DyslipidemiaChina
-
NovartisCompletedMetabolic SyndromeGermany
-
NovartisCompletedMixed Dyslipidemia | Heterozygous Familial HypercholesterolemiaSwitzerland
-
Novartis PharmaceuticalsCompleted
-
University of ZurichUniversity of BaselCompletedInsulin Resistance | Clinical Trial | Adipose Tissue, BrownSwitzerland
-
University of BolognaUnknown